Making a 'point' about the safe disposal of sharps in patients on biological therapiesHUSSAIN, W; OGDEN, S; LAVERY, D et al.British journal of dermatology (1951). 2008, Vol 159, Num 2, pp 491-492, issn 0007-0963, 2 p.Article

Adenoviruses for treatment of cancerKANERVA, Anna; HEMMINKI, Akseli.Annals of medicine (Helsinki). 2005, Vol 37, Num 1, pp 33-43, issn 0785-3890, 11 p.Article

Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centreWARREN, R. B; BROWN, B. C; LAVERY, D et al.British journal of dermatology (1951). 2010, Vol 163, Num 4, pp 859-862, issn 0007-0963, 4 p.Article

Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis: a one-year studyAJEGANOVA, S; FISKESUND, R; DE FAIRE, U et al.Clinical and experimental rheumatology (Testo stampato). 2011, Vol 29, Num 6, pp 942-950, issn 0392-856X, 9 p.Article

Effectiveness of Infliximab in Brazilian Children and Adolescents With Crohn Disease and Ulcerative Colitis According to Clinical Manifestations, Activity Indices of Inflammatory Bowel Disease, and Corticosteroid UseTIEMI, Juliana; KOMATI, Saito; SDEPANIAN, Vera Lucia et al.Journal of pediatric gastroenterology and nutrition. 2010, Vol 50, Num 6, pp 628-633, issn 0277-2116, 6 p.Article

Rituximab for rescue and maintenance therapy in rapidly progressive life-threatening antineutrophil cytoplasmic autoantibody-associated systemic vasculitisJOSE, Ricardo J. P; CHRYSOCHOU, Constantina; SHURRAB, Ala'a E et al.Scandinavian journal of urology and nephrology. 2010, Vol 44, Num 6, pp 459-462, issn 0036-5599, 4 p.Article

The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's diseaseKIERKUS, Jarosław; DADALSKI, Maciej; SZYMANSKA, Edyta et al.European journal of gastroenterology & hepatology. 2012, Vol 24, Num 5, pp 495-500, issn 0954-691X, 6 p.Article

Anti-inflammatory effect of biological treatment in patients with inflammatory bowel diseases: Calprotectin and IL-6 changes do not correspond to sRAGE changesMALICKOVA, Karin; KALOUSOVA, Marta; FUCIKOVA, Terezie et al.Scandinavian journal of clinical & laboratory investigation. 2010, Vol 70, Num 4, pp 294-299, issn 0036-5513, 6 p.Article

The 13th Annual Meeting of the Translational Research Cancer Centers Consortium (TrC3); Immune Suppression and the Tumor Microenvironment, Columbus, Ohio; March 1-2, 2010LESINSKI, Gregory B; CARSON, William E; REPASKY, Elizabeth A et al.Journal of immunotherapy (1997). 2010, Vol 33, Num 7, pp 659-662, issn 1524-9557, 4 p.Article

A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinomaKANERVA, A; BAUERSCHMITZ, G. J; YAMAMOTO, M et al.Gene therapy (Basingstoke). 2004, Vol 11, Num 6, pp 552-559, issn 0969-7128, 8 p.Article

A Phase II Study of the Survivin Suppressant YM155 in Patients With Refractory Diffuse Large B-Cell LymphomaCHESON, Bruce D; BARTLETT, Nancy L; VOSE, Julie M et al.Cancer. 2012, Vol 118, Num 12, pp 3128-3134, issn 0008-543X, 7 p.Article

A Pathogenetic Approach to Autoimmune Skin Disease Therapy: Psoriasis and Biological Drugs, Unresolved Issues, and Future DirectionsAYROLDI, Emira; BASTIANELLI, Alessandra; CANNARILE, Lorenza et al.Current pharmaceutical design (Print). 2011, Vol 17, Num 29, pp 3176-3190, issn 1381-6128, 15 p.Article

Immunobiological and Experimental Aspects of Malignant AstrocytomaNANO, R; CAPELU, E; FACOETTI, A et al.Anticancer research. 2009, Vol 29, Num 7, pp 2461-2465, issn 0250-7005, 5 p.Article

New and emerging therapies for inflammatory bowel diseasesGRIMM, Michael C.Journal of gastroenterology and hepatology. 2009, Vol 24, issn 0815-9319, S69-S74, SUP3Article

¿ Qué tiene de singular adalimumab? = WHAT IS SPECIAL ABOUT ADALIMUMAB?RODRIGUEZ-BLANCO, I; TORIBIO, J.Actas dermo-sifiliográficas (Ed. impresa). 2008, Vol 99, pp 28-32, issn 0001-7310, 5 p., SUP3Article

Risk of Infection and Prevention in Pediatric Patients With IBD: ESPGHAN IBD Porto Group CommentaryVEEREMAN-WAUTERS, Gigi; DE RIDDER, Lissy; ESCHER, Johanna C et al.Journal of pediatric gastroenterology and nutrition. 2012, Vol 54, Num 6, pp 830-837, issn 0277-2116, 8 p.Article

Endothelial progenitor cells: novel biomarker and promising cell therapy for cardiovascular diseaseSEN, Shaundeep; MCDONALD, Stephen P; COATES, P. Toby H et al.Clinical science (1979). 2011, Vol 120, Num 7-8, pp 263-283, issn 0143-5221, 21 p.Article

Anaphylactic Reaction to Anakinra in a Rheumatoid Arthritis Patient Intolerant to Multiple Nonbiologic and Biologic Disease-Modifying Antirheumatic DrugsDESAI, Ditina; GOLDBACH-MANSKY, Raphaela; MILNER, Joshua D et al.The Annals of pharmacotherapy. 2009, Vol 43, Num 5, pp 967-972, issn 1060-0280, 6 p.Article

Thrombotic thrombocytopenic purpura with the use of efalizumab for psoriasisTHACHIL, J; MARTLEW, V.British journal of dermatology (1951). 2008, Vol 158, Num 5, pp 1138-1139, issn 0007-0963, 2 p.Article

Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF)SCHWAAB, Thomas; TRETTER, Christopher P. G; ERNSTOFF, Marc S et al.The Prostate. 2006, Vol 66, Num 6, pp 667-674, issn 0270-4137, 8 p.Article

TNF-α as a promising therapeutic target in chronic asthma : a lesson from rheumatoid arthritisRUSSO, Cristina; POLOSA, Riccardo.Clinical science (1979). 2005, Vol 109, Num 2, pp 135-142, issn 0143-5221, 8 p.Article

Recommendations for the use of biologic therapy from the Italian Society for Rheumatology: off-label useTODOERTI, M; PIPITONE, N; MATUCCI-CERINIC, M et al.Clinical and experimental rheumatology (Testo stampato). 2011, Vol 29, Num 3, issn 0392-856X, S42-S62, SUP66Article

Cutaneous adverse effects of biological therapies for psoriasisROE, Esther; PUIG, Lluis; CORELLA, Francisca et al.EJD. European journal of dermatology. 2008, Vol 18, Num 6, pp 693-699, issn 1167-1122, 7 p.Article

The Spectrum of Tuberculosis Infection: New Perspectives in the Era of BiologicsDELOGU, Giovanni; GOLETTI, Delia.Journal of rheumatology. 2014, Vol 41, pp 11-16, issn 0315-162X, 6 p., SUP91Article

Methodological issues when measuring paid productivity loss in patients with arthritis using biologic therapies: an overview of the literatureVERSTAPPEN, Suzanne M. M; FAUTREL, Bruno; DADOUN, Sabrina et al.Rheumatology (Oxford. Print). 2012, Vol 51, Num 2, pp 216-229, issn 1462-0324, 14 p.Article